The U.S. Food and Drug Administration has approved the use of sound waves to break down tumors—a technique called histotripsy—in humans for liver treatment.
Liver fibrosis is associated with various liver injuries, including viral infection, inflammation, excess alcohol consumption, and metabolic dysfunction.
As one of just six sites in the country chosen for a new consortium of the National Institutes of Health (NIH), UTHealth Houston School of Public Health in Brownsville will use multi-omics in combination with environmental, epidemiologic, and clinical data, along with social determinants of health, to study non-alcoholic and non-viral liver disease in Hispanics/Latinos.
A study reveals genetic subtypes, biomarkers, gene and pathway targets for the development of new treatments for this liver disease
Below are some of the latest headlines in the Women's Health channel on Newswise.
Researchers at The University of Texas MD Anderson Cancer Center have discovered that certain nano-based cancer therapies may be less effective in younger patients, highlighting the need for further investigation into the impact of aging on the body’s ability to respond to treatment.
La cirrosis a menudo es consecuencia del consumo de alcohol crónico a largo plazo. Sin embargo, algunas personas que consumen poco o nada de alcohol pueden presentar cirrosis.
A cirroseé geralmente associada ao consumo prolongado e excessivo de álcool. No entanto, algumas pessoas que consomem pouco ou nenhum álcool podem acabar desenvolvendo a doença.
Close relatives of people with metabolic-associated fatty liver disease have a higher risk of developing liver cancer and dying from liver-related diseases, according to a national study from Karolinska Institute in Sweden published in The Journal of Hepatology.
Research updates in gastroenterology and hepatology from the September issue of The American Journal of Gastroenterology, the flagship journal of the American College of Gastroenterology.
Race and ethnicity may play a role in liver cancer, which disproportionately affects people of low socioeconomic status, as well as immigrants, veterans and incarcerated populations.
The zebrafish is one of the most powerful biomedical research tools in use today. Children's Hospital Los Angeles is using them to better understand what causes pediatric cancer.
Gene therapy with microRNA-22 produced better survival outcomes than the current FDA-approved drug for liver cancer and without noticeable toxicity in new mouse study.
$9 million grant awarded to researchers with UC San Diego School of Medicine supports new study of semaglutide for liver disease.
In a breakthrough in liver transplantation that may lead to the ability to connect more living donors and patients, a new matching system designed by a team led by Boston College economists enabled the world’s first four-way liver exchange and a cascade of additional matches.
A $3 million, five-year award from the National Institute of Environmental Health Sciences of the NIH aims to discover and validate the gene Х heavy metal (GXM) interactions in human livers and to understand their role in nonalcoholic fatty liver disease
La inteligencia artificial (IA) está capturando la imaginación del público a medida que el ritmo de la innovación se acelera considerablemente y las herramientas de IA fáciles de usar ofrecen nuevas posibilidades para transformar industrias enteras.
The Food and Drug Administration announced yesterday the approval of HEPZATO Kit to treat ocular melanoma that has spread to the liver. HEPZATO uses a hepatic delivery system to inject the chemotherapy drug melphalan into the liver, a procedure referred to as percutaneous hepatic perfusion (PHP). Moffitt Cancer Center’s Jonathan S. Zager, M.D., was the lead international principal investigator on the multinational FOCUS phase 3 clinical trial to test the procedure, which is manufactured by Delcath Systems, Inc.
Artificial intelligence (AI) is capturing the public imagination as the pace of innovation accelerates sharply and easy-to-use AI tools offer new possibilities to transform whole industries.
The researchers demonstrated that glucokinase activation was effective in lowering blood glucose in mice with high-fat diet-induced obesity, while it potentially raised the risk of increasing hepatic lipid accumulation that triggered the PERK-UPR pathway. Thus, this study provides clinical reference and theoretical basis for the application of glucokinase activator (GKA) in treating patients with type 2 diabetes (or combined with non-alcoholic fatty liver disease).
A brief roundup of news and story ideas from the experts at UCLA Health.
In a recent study published in the journal of Genes & Diseases, researchers have discovered a compelling link between a specific gut bacterium and the progression of atherosclerosis, a leading cause of cardiovascular diseases, such as heart attack and stroke. The culprit is a microbe known as Desulfovibrio desulfuricans (D. desulfuricans), found to be responsible for increasing intestinal permeability and prompting a potent inflammatory response, contributing to the disease's progression.
A new study analyzing toxins produced by Microcystis, the main type of cyanobacteria that compose the annual harmful algal bloom (HAB) in Lake Erie, suggests that the toxicity of the bloom may be overestimated in earlier warm months and underestimated later in the summer.
The Radiological Society of North America (RSNA) has launched the “RSNA 2023 Abdominal Trauma Detection AI Challenge” to explore whether artificial intelligence (AI) can be used to aid in the detection and classification of traumatic abdominal injuries.
Helen is an 8 1/2-year old gentle giant who’s fighting osteosarcoma and, through participation in a clinical trial through the Animal Cancer Care and Research Center, is helping develop a new cancer treatment. The dog's owners have a 1-year-old son enrolled in a clinical trial for a rare liver disease, which gave them the idea to also enroll Helen in a clinical trial.
New research shows how using molecular tools and alternative gene splicing can make a protein called CEACAM1 more protective against liver injury during transplantation, thus reducing organ injury and ultimately improving post-transplant outcomes.
Mercy Medical Center in Baltimore, Maryland, has been recognized by U.S. News & World Report’s “Best Hospitals” rankings for 2023-2024.
New insights into the underlying mechanisms of Type 2 diabetes and novel potential therapeutic targets for the disease were revealed in a recent study.
Valance Sams Sr.’s world was turned upside down 10 years ago when he was diagnosed with sarcoidosis, a rare inflammatory disease that caused a buildup of scar tissue on his heart and left him unable to work, exercise or even walk.
A new study, which involved experiments on mice and human patients, uncovered an important communication pathway between two molecules called CEACAM1 (CC1) and TIM-3, finding that the pathway plays a crucial role in controlling the body's immune response during liver transplantation.
A surgical team from Washington University School of Medicine in St. Louis recently performed the first robotic liver transplant in the U.S. in May at Barnes-Jewish Hospital.
The randomized controlled study was conducted by 15 liver transplant centers in the United States, including Ochsner Health Liver Transplant Institute, and compared the use of normothermic machine preservation (NMP)—which maintains the organ at normal body temperature-- with static cold storage (SCS) in 383 donor organs.
Fiscal year 2023, which ended June 30, proved to be the busiest year yet for Cedars-Sinai’s Comprehensive Transplant Center and Smidt Heart Institute, with more than 600 organs transplanted.
Doctors in Seattle are reporting a history-making case in which a patient received two donor organs, a liver and a heart, to prevent the extreme likelihood that her body would reject a donor heart transplanted alone. In this innovative case, the organ recipient’s own healthy liver was transplanted, domino-like, into a second patient who had advanced liver disease.
Researchers found increasing cases of the alcohol-related liver illness from 2016 through 2020, but the rise was particularly pronounced the year COVID-19 arrived in the U.S. in 2020, which saw a 12.4% increase over 2019 levels.
Scientists at St. Jude Children’s Research Hospital used genomics to inform the creation of genetic and new cell-line models for hepatoblastoma, which pointed toward the DNA damage repair pathway as a promising therapeutic route.
The July issue of The American Journal of Gastroenterology includes new ACG Clinical Guidelines on Acute Liver Failure, addressing a time-sensitive condition gastroenterologists and hepatologists encounter.
The arrival of summer marks the return of a cherished activity: backyard grilling. A UT Southwestern Medical Center toxicologist offers some cautionary guidelines to help you and your guests avoid food poisoning.
A team of surgical experts led by Gregory J. Tiesi, M.D., FACS, FSSO, began implanting hepatic artery infusion pumps in patients at Hackensack Meridian Jersey Shore University Medical Center in June. They are among the first in New Jersey to provide the pump for patients.
Collaborative work by teams at the Department of Medicine and Life Sciences (MELIS) at Pompeu Fabra University (UPF), University of California, Irvine (UCI), and the Institute for Research in Biomedicine (IRB Barcelona) has shown that interplay between circadian clocks in liver and skeletal muscle controls glucose metabolism.
Researchers with UC San Diego School of Medicine identified a potential new drug that improved liver fibrosis in patients with NASH by 27%.
A genetic marker discovered by UT Southwestern Medical Center researchers could help physicians predict which patients with hepatocellular carcinoma are most likely to develop resistance to the drug lenvatinib. The finding, published in the journal Gastroenterology, may lead to alternative treatments for the most common form of liver cancer.
Los investigadores de Mayo Clinic identificaron un amplio rango de sustancias químicas ambientales en la bilis humana de pacientes con colangitis esclerosante primaria, una enfermedad hepática crónica y poco común que afecta los conductos biliares. El estudio, que se publicó en Exposome, representa una nueva frontera de investigación en el Centro de Medicina Personalizada en Mayo Clinic que explora el exposoma, la medida en que el ambiente contribuye a las enfermedades y la salud.
Pesquisadores da Mayo Clinic identificaram uma ampla variedade de substâncias químicas presentes no ambiente na bile humana em pacientes com colangite esclerosante primária, uma doença hepática crônica rara nos dutos biliares. O estudo, publicado na revista Exposome, representa uma nova frente de pesquisa do Centro de Medicina Individualizada da Mayo Clinic que estuda o expossoma (a medida dos fatores ambientais que contribuem para a saúde e o aparecimento de doenças).
مدينة روتشستر، ولاية مينيسوتا — استطاع الباحثون في مايو كلينك تحديد عدد من الكيماويات البيئية في العصارة الصفاروية للمرضى المصابين بالْتِهابُ الأَقْنِيَةِ الصَّفْراوِيَّةِ المُصَلِّب الأوَّلي وهو مرض كبدي مزمن نادر يصيب القنوات الصفراوية. يمثل البحث المنشور حول الإكسبوزوم فتحًا جديدًا في مجال البحث العلمي، أنجزه مركز مايو كلينك للطب الفردي. يحاول هذا البحث فهم خبايا الإكسبوزوم، وهو قياس مدى تأثير العوامل البيئية على الصحة والإصابة بالأمراض.
Dozens of children die each year in the U.S. while waiting for a new liver. A new analysis suggests that greater use of partial liver transplants — either from a living donor or by splitting a deceased donor’s liver for two recipients — could save many of these young lives.
Mayo Clinic researchers have identified a diverse range of environmental chemicals in human bile in patients with primary sclerosing cholangitis, a rare, chronic liver disease of the bile ducts. The study, published in Exposome, represents a new frontier of research at Mayo Clinic's Center for Individualized Medicine that explores the exposome, the measure of environmental contributors to disease and health.
The percent of metabolic associated fatty liver disease (MAFLD), the leading global cause of liver disease, is increasing in U.S. adults, according to a study presented Friday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
